S Vajapeyam1, D Brown2, C Billups3, Z Patay4, G Vezina5, M S Shiroishi6, M Law7, P Baxter8, A Onar-Thomas3, J R Fangusaro9, I J Dunkel10, T Y Poussaint11. 1. From the Radiology (S.V., T.Y.P.), Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts sridhar.vajapeyam@childrens.harvard.edu. 2. DF/HCC Tumor Imaging Metrics Core (D.B.), Massachusetts General Hospital, Boston, Massachusetts. 3. Biostatistics (C.B., A.O.-T.). 4. Diagnostic Imaging (Z.P.), St. Jude Children's Research Hospital, Memphis, Tennessee. 5. Radiology (G.V.), Children's National Medical Center, Washington, DC. 6. Radiology (M.S.S.), Keck Medical Center of USC, Los Angeles, California. 7. Neuroscience (M.L.), Monash University, Melbourne, Australia. 8. Cancer and Hematology Center (P.B.), Texas Children's Hospital, Houston, Texas. 9. Aflac Cancer and Blood Disorders Center (J.R.F.), Children's Healthcare of Atlanta, Atlanta, Georgia. 10. Pediatrics (I.J.D.), Memorial Sloan Kettering Cancer Center, New York, New York. 11. From the Radiology (S.V., T.Y.P.), Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND AND PURPOSE: Diffuse intrinsic pontine glioma is a lethal childhood brain cancer with dismal prognosis and MR imaging is the primary methodology used for diagnosis and monitoring. Our aim was to determine whether advanced diffusion, perfusion, and permeability MR imaging metrics predict survival and pseudoprogression in children with newly diagnosed diffuse intrinsic pontine glioma. MATERIALS AND METHODS: A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium. Standard MR imaging, DWI, dynamic contrast-enhanced perfusion, and DSC perfusion were performed at baseline and approximately every 2 months throughout treatment. ADC histogram metrics of T2-weighted FLAIR and enhancing tumor volume, dynamic contrast-enhanced permeability metrics for enhancing tumors, and tumor relative CBV from DSC perfusion MR imaging were calculated. Baseline values, post-radiation therapy changes, and longitudinal trends for all metrics were evaluated for associations with survival and pseudoprogression. RESULTS: Fifty children were evaluable for survival analyses. Higher baseline relative CBV was associated with shorter progression-free survival (P = .02, Q = 0.089) and overall survival (P = .006, Q = 0.055). Associations of higher baseline mean transfer constant from the blood plasma into the extravascular extracellular space with shorter progression-free survival (P = .03, Q = 0.105) and overall survival (P = .03, Q = 0.102) trended toward significance. An increase in relative CBV with time was associated with shorter progression-free survival (P < .001, Q < 0.001) and overall survival (P = .004, Q = 0.043). Associations of longitudinal mean extravascular extracellular volume fraction with progression-free survival (P = .03, Q = 0.104) and overall survival (P = .03, Q = 0.105) and maximum transfer constant from the blood plasma into the extravascular extracellular space with progression-free survival (P = .03, Q = 0.102) trended toward significance. Greater increases with time were associated with worse outcomes. True radiologic progression showed greater post-radiation therapy decreases in mode_ADC_FLAIR compared with pseudoprogression (means, -268.15 versus -26.11, P = .01.) CONCLUSIONS: ADC histogram, perfusion, and permeability MR imaging metrics in diffuse intrinsic pontine glioma are useful in predicting survival and pseudoprogression.
BACKGROUND AND PURPOSE: Diffuse intrinsic pontine glioma is a lethal childhood brain cancer with dismal prognosis and MR imaging is the primary methodology used for diagnosis and monitoring. Our aim was to determine whether advanced diffusion, perfusion, and permeability MR imaging metrics predict survival and pseudoprogression in children with newly diagnosed diffuse intrinsic pontine glioma. MATERIALS AND METHODS: A clinical trial using the poly (adenosine diphosphate ribose) polymerase (PARP) inhibitor veliparib concurrently with radiation therapy, followed by maintenance therapy with veliparib + temozolomide, in children with diffuse intrinsic pontine glioma was conducted by the Pediatric Brain Tumor Consortium. Standard MR imaging, DWI, dynamic contrast-enhanced perfusion, and DSC perfusion were performed at baseline and approximately every 2 months throughout treatment. ADC histogram metrics of T2-weighted FLAIR and enhancing tumor volume, dynamic contrast-enhanced permeability metrics for enhancing tumors, and tumor relative CBV from DSC perfusion MR imaging were calculated. Baseline values, post-radiation therapy changes, and longitudinal trends for all metrics were evaluated for associations with survival and pseudoprogression. RESULTS: Fifty children were evaluable for survival analyses. Higher baseline relative CBV was associated with shorter progression-free survival (P = .02, Q = 0.089) and overall survival (P = .006, Q = 0.055). Associations of higher baseline mean transfer constant from the blood plasma into the extravascular extracellular space with shorter progression-free survival (P = .03, Q = 0.105) and overall survival (P = .03, Q = 0.102) trended toward significance. An increase in relative CBV with time was associated with shorter progression-free survival (P < .001, Q < 0.001) and overall survival (P = .004, Q = 0.043). Associations of longitudinal mean extravascular extracellular volume fraction with progression-free survival (P = .03, Q = 0.104) and overall survival (P = .03, Q = 0.105) and maximum transfer constant from the blood plasma into the extravascular extracellular space with progression-free survival (P = .03, Q = 0.102) trended toward significance. Greater increases with time were associated with worse outcomes. True radiologic progression showed greater post-radiation therapy decreases in mode_ADC_FLAIR compared with pseudoprogression (means, -268.15 versus -26.11, P = .01.) CONCLUSIONS: ADC histogram, perfusion, and permeability MR imaging metrics in diffuse intrinsic pontine glioma are useful in predicting survival and pseudoprogression.
Authors: Alissa A Thomas; Julio Arevalo-Perez; Thomas Kaley; John Lyo; Kyung K Peck; Weiji Shi; Zhigang Zhang; Robert J Young Journal: J Neurooncol Date: 2015-08-15 Impact factor: 4.130
Authors: Rafael Ceschin; Mehmet Kocak; Sridhar Vajapeyam; Ian F Pollack; Arzu Onar-Thomas; Ira J Dunkel; Tina Young Poussaint; Ashok Panigrahy Journal: J Neurooncol Date: 2019-02-27 Impact factor: 4.130
Authors: R Ceschin; B F Kurland; S R Abberbock; B M Ellingson; H Okada; R I Jakacki; I F Pollack; A Panigrahy Journal: AJNR Am J Neuroradiol Date: 2015-09-03 Impact factor: 3.825
Authors: Ashley E Conway; Wilburn E Reddick; Yimei Li; Ying Yuan; John O Glass; Justin N Baker; Larry E Kun; Alberto Broniscer; Zoltan Patay Journal: Neuroradiology Date: 2014-03-14 Impact factor: 2.804
Authors: David Castel; Cathy Philippe; Raphaël Calmon; Ludivine Le Dret; Nathalène Truffaux; Nathalie Boddaert; Mélanie Pagès; Kathryn R Taylor; Patrick Saulnier; Ludovic Lacroix; Alan Mackay; Chris Jones; Christian Sainte-Rose; Thomas Blauwblomme; Felipe Andreiuolo; Stephanie Puget; Jacques Grill; Pascale Varlet; Marie-Anne Debily Journal: Acta Neuropathol Date: 2015-09-23 Impact factor: 17.088
Authors: Anastasia Zikou; Chrissa Sioka; George A Alexiou; Andreas Fotopoulos; Spyridon Voulgaris; Maria I Argyropoulou Journal: Contrast Media Mol Imaging Date: 2018-12-02 Impact factor: 3.161
Authors: S Vajapeyam; D Brown; A Ziaei; S Wu; G Vezina; J S Stern; A Panigrahy; Z Patay; B Tamrazi; J Y Jones; S S Haque; D S Enterline; S Cha; B V Jones; K W Yeom; A Onar-Thomas; I J Dunkel; M Fouladi; J R Fangusaro; T Y Poussaint Journal: AJNR Am J Neuroradiol Date: 2022-02-24 Impact factor: 3.825
Authors: Margot A Lazow; Martijn T Nievelstein; Adam Lane; Pratiti Bandopadhayhay; Mariko DeWire-Schottmiller; Maryam Fouladi; John W Glod; Robert J Greiner; Lindsey M Hoffman; Trent R Hummel; Lindsay Kilburn; Sarah Leary; Jane E Minturn; Roger Packer; David S Ziegler; Brooklyn Chaney; Katie Black; Peter de Blank; James L Leach Journal: Neuro Oncol Date: 2022-09-01 Impact factor: 13.029
Authors: Vittorio Stumpo; Lelio Guida; Jacopo Bellomo; Christiaan Hendrik Bas Van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-05 Impact factor: 6.639
Authors: Catherine Coolens; Matt N Gwilliam; Paula Alcaide-Leon; Isabella Maria de Freitas Faria; Fabio Ynoe de Moraes Journal: Cancers (Basel) Date: 2021-05-23 Impact factor: 6.639